US Patent

US12576253 — Drug delivery device with intravesical tolerability

Formulation · Assigned to Taris Biomedical LLC · Expires 2030-12-17 · 5y remaining

Vulnerability score 61/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a drug delivery device that can be fully deployed within a patient's bladder and is designed to be well-tolerated.

USPTO Abstract

Intravesical devices are provided that are wholly deployable within the bladder of a patient in need of treatment and are well tolerated by the patient. The device may include an elastic body having a retention shape having (i) dimensions that provide intravesical mobility and that prevent voiding of the medical device through the urethra, and (ii) dimensions, buoyancy, or both, that exclude the medical device from entering the orifices of the ureters. The elastic body may exert a maximum acting force less than 1 N when compressed to a shape with a maximum dimension in any dimension of 3 cm. The device may include a drug for controlled release within the bladder, for treatment of the bladder or a regional tissue. Methods of treatment are also provided that include selecting a patient in need of treatment in the bladder where tolerability of the treatment is a primary concern.

Drugs covered by this patent

Patent Metadata

Patent number
US12576253
Jurisdiction
US
Classification
Formulation
Expires
2030-12-17
Drug substance claim
No
Drug product claim
Yes
Assignee
Taris Biomedical LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.